Pediatrix Medical Group (MD) is highlighted as a potential growth stock with a #3 (Hold) Zacks Rank and an A VGM Score. The company shows strong growth prospects with forecasted year-over-year earnings growth of 13.7% for fiscal 2026, a B Growth Style Score, and a positive average earnings surprise of +17.4%. Two analysts revised earnings estimates higher in the last 60 days, with the consensus estimate increasing to $2.32 per share.

Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.

Cencora reported Q3 fiscal 2026 adjusted EPS of $4.48, beating consensus estimates by 2.5%, with 12% year-over-year earnings growth. Revenue rose 5.1% to $84.76 billion but slightly missed expectations. The company raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and increased operating income growth outlook to 13-14%. However, post-earnings estimates have trended downward, and the stock received a Zacks Rank #3 (Hold) rating.

Pediatrix Medical Group beat Q2 2026 earnings expectations with adjusted EPS of 63 cents (10.5% above consensus) and revenue of $487.8 million (2.2% above estimate), driven by improved cash collection and favorable payor mix. However, the company faced headwinds from lower patient volumes and higher operating costs. Management reaffirmed 2026 adjusted EBITDA guidance of $280-$300 million. The stock has gained 3.4% since the earnings report and carries a Zacks Rank #3 (Hold) rating with an overall VGM Score of A.

ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.

Pediatrix Medical Group reported strong Q2 2025 earnings, with non-GAAP EPS of $0.53 beating analyst expectations. Despite a 7.4% revenue decline due to practice divestitures, the company showed growth in hospital-based neonatal services and raised its adjusted EBITDA guidance.

MONTRÉAL, 25 juin 2024 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V: MD), en partenariat avec Probe Gold Inc. (« Probe »), a le plaisir d’annoncer la reprise des travaux d’exploration sur la découverte d’un système minéralisé en cuivre-or-argent-molybdène (« Cu-Au-Ag-Mo ») effectuée en 2022 sur la propriété La Peltrie Option (« la Propriété »). Cet important système minéralisé est situé à 15 kilomètres au sud-est du gîte aurifère Zone 58N détenu par Agnico Eagle et à 25 kilomètres à l’ouest de l’ancienne mine Selbaie qui a produit 56,9 Mt titrant 0,87% Cu, 1,85% Zn, 39 g/t Ag et 0,55 g/t Au (production historique).

MONTREAL, June 25, 2024 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Probe Gold Inc. (“Probe”), is pleased to announce that exploration work will resume on the copper-gold-silver-molybdenum (“Cu-Au-Ag-Mo”) discovery made in 2022 on the La Peltrie Option (the “Property”). This significant mineralized system is located 15 kilometres southeast of Agnico Eagle’s Zone 58N gold deposit and 25 kilometres west of the former Selbaie mine, which produced 56.9 Mt grading 0.87% Cu, 1.85% Zn, 39 g/t Ag, and 0.55 g/t Au (historical production).

Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MONTRÉAL, 04 juin 2024 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V : MD) a le plaisir d’annoncer son programme d’exploration pour l’été 2024 dans le cadre de l’alliance stratégique (« l’Alliance ») avec SOQUEM inc. (« SOQUEM ») pour l’exploration de la Fosse du Labrador au Nunavik. Ce programme, d’un budget conjoint d’1 million $, s’inscrit dans la continuité des travaux effectués depuis 2021. Ces travaux visent à identifier de nouveaux secteurs minéralisés dans ce vaste territoire à haut potentiel de découverte.

MONTREAL, June 04, 2024 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce its summer 2024 exploration program under the Strategic Alliance (the “Alliance”) with SOQUEM Inc. (“SOQUEM”) for exploration in the Labrador Trough in Nunavik. With a joint budget of $1 million, this program is the continuation of work carried out since 2021 and aims to identify new mineralized areas in this vast territory with high-discovery potential.